CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
SOM230biological
Likely dose
SOM230 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01639352
NCT01639352Phase 2Completed
CompareCT.gov

Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Lynn Feun·interventional·Posted Jul 12, 2012·Updated Jul 12, 2017

In Brief

A Phase 2 clinical trial evaluating SOM230 for Hepatocellular Carcinoma. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The hypothesis of this clinical trial is that hepatocellular carcinomas contain somatostatin receptors which make them sensitive to the inhibitory effects of a new somatostatin analog, SOM230. This analog has greater and broader binding affinity to somatostatin receptors compared to the current drug in use, sandostatin LAR. Thus, SOM230 has the potential to be more effective in the treatment of patients with hepatocellular carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2012
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 14.0 years ago

Interventions

SOM230biological

Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.